Sylvester Comprehensive Cancer Center

  • 20230337 - Chauhan Aman

  • Investigator:
    Aman Chauhan
    RCname Email

    Coordinator:

    IRB: 20230337

    SDG: GI
    Disease Site(s):

    Multiple

    Sponsor: ETCTN

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    Phase II Randomized Control Trial of Triapine Plus Lutetium Lu 177 Dotatate Versus Lutetium Lu 177 Dotatate Alone for Well-Differentiated Somatostatin Receptor-Positive Neuroendocrine Tumors

    Eligibility Criteria - NCT05724108 *This information has been extracted from " www.clinicaltrials.gov"

  • 20211110 - Ezenwajiaku Nkiruka

  • Investigator:
    Nkiruka Ezenwajiaku
    RCname Email

    Coordinator:

    IRB: 20211110

    SDG: GI
    Disease Site(s):

    Pancreas

    Sponsor: ECOG

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

    Eligibility Criteria - NCT04858334 *This information has been extracted from " www.clinicaltrials.gov"

  • 20221105 - Feun Lynn

  • Investigator:
    Lynn Feun
    RCname Email

    Coordinator:

    IRB: 20221105

    SDG: GI
    Disease Site(s):

    Liver

    Sponsor: ACCRU

    Enrolling Sites:

    Sylvester

    Title:

    A Phase II study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab.

    Eligibility Criteria - NCT05199285 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220166 - Hosein Peter

  • Investigator:
    Peter Hosein
    RCname Email

    Coordinator:

    IRB: 20220166

    SDG: GI
    Disease Site(s):

    Pancreas

    Sponsor: SWOG

    Enrolling Sites:

    Sylvester

    Title:

    Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors

    Eligibility Criteria - NCT05040360 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220171 - Hosein Peter

  • Investigator:
    Peter Hosein
    RCname Email

    Coordinator:

    IRB: 20220171

    SDG: GI
    Disease Site(s):

    Pancreas

    Sponsor: SCCC

    Enrolling Sites:

    Plantation
    Sylvester

    Title:

    A phase 1 trial of combined MEK, STAT3 and PD-1 inhibition in metastatic pancreatic ductal adenocarcinoma

    Eligibility Criteria - NCT05440942 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231247 - Hosein Peter

  • Investigator:
    Peter Hosein
    RCname Email

    Coordinator:

    IRB: 20231247

    SDG: GI
    Disease Site(s):

    Colon,Pancreas

    Sponsor: Elicio Therapeutics Inc

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects with Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS viral oncogene homolog (NRAS) Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

    Eligibility Criteria - NCT05726864 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190846 - Penedo Frank

  • Investigator:
    Frank Penedo
    RCname Email

    Coordinator:

    IRB: 20190846

    SDG: GI
    Disease Site(s):

    Pancreas

    Sponsor: SCCC

    Enrolling Sites:

    JMH
    Sylvester
    UMH

    Title:

    Quality of Life Program for Pancreatic Cancer Patients

    Eligibility Criteria - NCT04815746 *This information has been extracted from " www.clinicaltrials.gov"